Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
To read the full story
ORGANIZATION
- Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
- Self-Medication and Proper Drug Pricing 2 Sides of the Same Coin: Professor
November 8, 2024
- Japan Wholesaler Group to Continue Stressing Plight of Supply Disruption
October 25, 2024
- Drug Therapy for Fetal Tachyarrhythmia Gets 1st Health Coverage in Japan
October 21, 2024
- Off-Year Price Revision Has Accomplished Mission: JPMA Exec
October 18, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…